Drug firm Alembic Pharmaceuticals is looking at filing 100 abbreviated new drug applications (ANDAs) with the US health regulator United States Food and Drug Administration (USFDA) over the next three years starting this fiscal as part of its expansion plans. The company is also aiming to launch up to 12 products per year in America during this time.
Aligned with the R&D efforts, the company is creating the requisite manufacturing infrastructure for ensuring timely supplies upon receiving regulatory approvals. Around 90 per cent of the company's R&D resources are allocated towards developing products for the US markets which, in turn, can be leveraged for strengthening presence in other regulated markets.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1783.55 |
| Dr. Reddys Lab | 1277.80 |
| Cipla | 1400.70 |
| Zydus Lifesciences | 1088.90 |
| Lupin | 2268.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: